ACM
ELVN icon

ADAR1 Capital Management’s Enliven Therapeutics ELVN Stock Holding History

ADAR1 Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Buy
387,718
+58,178
+18% +$2.47M 0.9% 24
2026
Q1 		$12.9M Buy
329,540
+299,540
+998% +$8.3M 0.76% 33
2025
Q4 		$462K Buy
+30,000
New +$598K 0.03% 188

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ADAR1 Capital Management's ELVN Position: Q2 2026 in Review

ADAR1 Capital Management increased its Enliven Therapeutics (ELVN) stake by 18% in Q2 2026, buying an estimated $2.47M and bringing the position to 387,718 shares worth $19.7M. The position accounts for 0.9% of the portfolio, ranked #24.

ADAR1 Capital Management first reported a position in ELVN in Q4 2025 and has held it in 3 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • ADAR1 Capital Management held 387,718 shares of Enliven Therapeutics worth $19.7M as of Q2 2026.
  • ADAR1 Capital Management bought 58,178 Enliven Therapeutics shares in Q2 2026, an estimated $2.47M.
  • Enliven Therapeutics made up 0.9% of ADAR1 Capital Management's portfolio in Q2 2026, its #24 holding.
  • ADAR1 Capital Management first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.